Cargando…
Bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis of randomized controlled trials
Bevacizumab, as antibodies, were applied to inhibit tumor angiogenesis by preventing activation of vascular endothelial growth factor receptor. We analyzed four clinical trials, including 607 patients, to investigate the efficacy and safety of bevacizumab when combined with chemotherapy for the trea...
Autores principales: | Yang, Shou-Bo, Gao, Kai-Di, Jiang, Tao, Cheng, Shu-Jun, Li, Wen-Bin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593645/ https://www.ncbi.nlm.nih.gov/pubmed/28915674 http://dx.doi.org/10.18632/oncotarget.16924 |
Ejemplares similares
-
Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials
por: Du, Chigang, et al.
Publicado: (2016) -
The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials
por: Jang, Hyun Joo, et al.
Publicado: (2017) -
Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis
por: Vogel, Arndt, et al.
Publicado: (2023) -
Surgery plus chemotherapy versus chemotherapy alone in primary intestinal lymphoma: a meta-analysis
por: Shu, Yefei, et al.
Publicado: (2021) -
Efficacy and Safety of Bevacizumab in Pretreated Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
por: Li, Zhijun, et al.
Publicado: (2022)